Montelukast Ametas (Montelukast)

Montelukast works by selectively antagonizing the cysteinyl leukotriene receptor CysLT1. This blocks leukotrienes D4, E4 and related mediators from triggering bronchoconstriction, mucus production, and inflammatory cell recruitment, thereby easing airway narrowing and allergic inflammation.

The dosage of Montelukast Ametas is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and clinical response. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for montelukast in pregnancy are limited, so it should only be used if the potential benefit justifies the risk. During breastfeeding, the drug passes into milk in small amounts; mothers should discuss potential risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or those who prefer a once‑daily tablet, though it does not replace rescue bronchodilators for acute attacks.

Montelukast Ametas should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. Swallow the tablet whole; do not crush, chew, or split it unless specifically instructed by a healthcare professional.

Serious but rare risks include severe allergic reactions such as rash, angioedema, or anaphylaxis, as well as neuropsychiatric events like depression, anxiety, or suicidal thoughts. Liver enzyme elevations have also been reported; patients should report any unusual symptoms promptly.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe liver impairment, and it is not recommended for children under the age for which the specific formulation is approved without medical supervision.